Details for New Drug Application (NDA): 216620
✉ Email this page to a colleague
NDA 216620 describes ELTROMBOPAG OLAMINE, which is a drug marketed by Annora Pharma and is included in one NDA. Additional details are available on the ELTROMBOPAG OLAMINE profile page.
The generic ingredient in ELTROMBOPAG OLAMINE is eltrombopag olamine. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag olamine profile page.
The generic ingredient in ELTROMBOPAG OLAMINE is eltrombopag olamine. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag olamine profile page.
Summary for 216620
| Tradename: | ELTROMBOPAG OLAMINE |
| Applicant: | Annora Pharma |
| Ingredient: | eltrombopag olamine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 12.5MG ACID/PACKET | ||||
| Approval Date: | Apr 18, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 25MG ACID/PACKET | ||||
| Approval Date: | Apr 18, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
